Efficacy of thoracic paravertebral block with liposomal bupivacaine for postoperative analgesia in patients undergoing liver resection: A randomized controlled trial
Authors' conclusion
TPVB-administered LB reduced total opioid consumption postoperatively in patients undergoing hepatectomy in the first 72 h.
Study context
- Population
- Patients undergoing liver resection93 analysed
- Participants
- 96 patients
- Comparison
- Thoracic paravertebral block (TPVB) with liposomal bupivacaine vs standard bupivacaine
- Primary endpoint
- Cumulative opioid consumption (mg oral morphine equivalent)
- Follow-up
- First 72 h
Methodological detailsprospective, single-blind
- Prospective
- Single-blind
Primary result
As reported in the abstract
P = 0.041
Secondary outcomes
Time to first opioid use, plasma bupivacaine and TNF-α levels
- Time to first opioid use longer and plasma bupivacaine and TNF-α levels greater postoperatively in liposomal bupivacaine (LB) vs standard bupivacaine (SB)
Other secondary outcomes (QoR-40 AUC, visual analog scale (VAS) AUC, other inflammatory factors, sleep quality at 3 months)
- No difference between the two groups
Safety
- No adverse events in this study
Original publication
Efficacy of thoracic paravertebral block with liposomal bupivacaine for postoperative analgesia in patients undergoing liver resection: A randomized controlled trial. J Clin Anesth. Published 14 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →